| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the last three months, 4 analysts have published ratings on 4D Molecular Therapeutics (NASDAQ:FDMT), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 0 | 0 | 0 |
| Last 30D | 2 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for 4D Molecular Therapeutics, presenting an average target of $28.25, a high estimate of $38.00, and a low estimate of $25.00. Experiencing a 5.04% decline, the current average is now lower than the previous average price target of $29.75.
The perception of 4D Molecular Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Salveen Richter | Roth Capital | Lowers | Buy | $38.00 | $44.00 |
| Geulah Livshits | Chardan Capital | Maintains | Buy | $25.00 | $25.00 |
| Geulah Livshits | Chardan Capital | Maintains | Buy | $25.00 | $25.00 |
| Geulah Livshits | Chardan Capital | Maintains | Buy | $25.00 | $25.00 |
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of 4D Molecular Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on 4D Molecular Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: 4D Molecular Therapeutics's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -50.0%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: 4D Molecular Therapeutics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -342657.14%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): 4D Molecular Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -9.79%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): 4D Molecular Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -8.92%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: 4D Molecular Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.05.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: FDMT
